Buying the Dip in Cabaletta After the EULAR Sell-Off

Hook & thesis

Shares of Cabaletta Bio (CABA) are down from recent highs despite clinical headlines that, on paper, should have been a rallying point. The company presented updated safety and efficacy data for its rese-cel program at the EULAR 2025 congress (06/11/2025) showing most treated patients achieved clinically meaningful responses while off immunomodulators and steroids. Instead of a sustained bullish move, the stock has pulled back to roughly $3.00 — a level that now offers a favorable asymmetric trade for disciplined buyers.

My thesis is straightforward: the market sold the EULAR event as a discrete news cycle and trimmed exposure into biotech strength. That reaction has created a tactical long opportunity into a pipeline with regulatory alignment on a registrational path for myositis, an RMAT designation, and a safety narrative that differentiates rese-cel from traditional cell therapies. I am initiating a long trade with a clear entry, stop and target and with the expectation that key development and regulatory milestones over the next 180 trading days will re-rate the stock higher.

What Cabaletta does and why the market should care

Cabaletta develops engineered T cell therapies that selectively deplete B cells producing pathogenic autoantibodies using a chimeric autoantibody receptor platform. That makes rese-cel a potentially disease-modifying approach for B cell-mediated autoimmune diseases where chronic immunosuppression is the current standard. The company is clinical-stage and focused on indications like myositis and systemic lupus erythematosus (SLE).

The market cares because successful cell therapy in autoimmunity would upend multi-billion-dollar chronic treatment markets and create a pricing and adoption pathway distinct from oncology CAR-T. Regulatory progress matters: Cabaletta announced alignment with the FDA on registrational cohorts for RESET-Myositis and is targeting a BLA submission for myositis by 2027 (announcement 05/29/2025) and received RMAT designation. Those are high-value readthroughs if registrational trails proceed cleanly.

Concrete financial and technical picture

Why the pullback looks like an overreaction

Two features stand out. First, the EULAR presentation on 06/11/2025 emphasized safety and on-treatment durability while off steroids and immunomodulators — an especially important message in autoimmune cell therapy where CRS, ICANS and infections are major investor concerns. The company previously reported no CRS or ICANS in initial patients (05/15/2024 update).

Second, valuation is still tethered to near-term clinical and regulatory milestones rather than peak-market potential. At a market cap below $500M and enterprise value near $383M, the stock sits well under what a successful registrational program in myositis could justify. With cash-like per-share assets present and a clear regulatory path (RMAT + FDA alignment), the downside appears better defined than the upside potential if registrational execution continues.

Valuation framing

This is an early-stage clinical biotech valuation: negative earnings (EPS -$1.08), meaningful cash burn (free cash flow -$143.3M) and no commercial revenue. Market cap of ~$478M reflects a mix of optimism for the pipeline and uncertainty about registrational and manufacturing risk. Comparing to historical levels: the stock traded as high as $4.23 over the last 52 weeks; a return to that level from $3.00 implies ~40% upside if the company simply recaptures prior sentiment. More importantly, the market is pricing future upside into regulatory progress rather than into eventual peak sales, which is appropriate but creates tactical buying windows on sell-offs tied to micro volatility.

In short, this is not a discounted cash flow story today; it is a clinical-readout-and-regulatory-progress valuation. The combination of RMAT and a public commitment to submit a BLA by 2027 for myositis gives a clearer path to value realization than many peers at a similar stage.

Catalysts to watch (near and medium term)

• Registrational trial initiation updates and cohort expansion details for RESET-Myositis - directional for regulatory timeline and sample size.
• FDA interactions and advice around endpoints and potential surrogate markers - progress reduces regulatory risk and compresses uncertainty.
• Additional clinical data releases at conferences or company updates that deepen safety and durability story across myositis, SLE and scleroderma.
• Operational updates on manufacturing scale-up or partnerships that address commercial readiness and cost of goods.

Trade plan (actionable)

Trade idea: go long CABA with the intent to hold into near-to-mid phase registrational catalysts over a long-term horizon.

• Entry: Buy at $3.00 (current price).
• Stop loss: $2.50 - invalidates the set-up by signaling either further negative news flow or a breakdown below recent technical support.
• Target: $4.20 - represents a move back to near the 52-week high and captures value re-rating if registrational clarity or positive follow-on data materializes.
• Position horizon: long-term (180 trading days) - this timeframe allows for trial enrollment updates, FDA interactions, or incremental data releases that typically move clinical names out of headline-driven volatility and toward fundamental re-rating.

Why these levels? $2.50 sits below near-term technical support and limits downside to a defined amount (~17% from entry). The $4.20 target is a realistic re-rating near recent highs and represents a reasonable liquidity tap for this capped market-cap stock. Expect volatility; use size discipline so a stop is meaningful but not portfolio-destabilizing.

Risks and counterarguments

• Clinical execution risk - early safety and efficacy are encouraging but larger registrational cohorts can reveal new safety signals or weaker efficacy. A negative registrational readout would severely damage valuation.
• Regulatory risk - alignment with the FDA to date is positive, but final approval hinges on trial design and endpoint selection. Regulatory requests for additional data or larger trials would push timelines and costs.
• Cash burn and funding risk - free cash flow is materially negative (recent figure shows -$143.3M). If cash runway shortens, dilution through secondary offerings or partnerships could occur and pressure the share price.
• Manufacturing and commercial execution - cell therapies require scalable, cost-effective manufacturing. Delays or high COGS could reduce future commercial margins and investor appetite.
• Short interest and technical risk - short interest is elevated (~26.24M shares), which can exacerbate downside on negative news and create whipsaw on volatility; conversely, it could contribute to sharp rallies if sentiment flips.

Counterargument: The principal counterargument is that the market is correctly pricing the company’s risk profile: clinically promising but capital intensive and early-stage. Investors may prefer to wait for registrational signals or stronger cash visibility before redeploying capital. That is a reasonable stance; if you are uncomfortable with binary clinical outcomes or potential near-term dilution, this trade is not for you. My view is that the current price compresses too much of the upside while not fully reflecting the weight of recent regulatory alignment and safety messaging.

What would change my mind

I would abandon this long if we see any of the following: (1) an updated clinical dataset showing safety concerns (CRS, ICANS, serious infections) in larger cohorts, (2) an FDA request for significantly larger trials that pushes BLA timelines materially beyond current guidance, or (3) a capital raise at a steep discount that meaningfully dilutes current shareholders and signals cash runway problems.

Conclusion

Buying CABA at $3.00 is a tactical, high-conviction long based on a favorable risk-reward after the EULAR sell-off. The company has colored the clinical and regulatory path with positive safety data, RMAT designation and explicit BLA ambitions for myositis. Those factors, together with a sub-$500M market cap and a stock that has returned toward its 52-week low-mid range, make a disciplined long trade attractive. Use the specified entry, stop and target, size appropriately for a high-risk biotech, and treat the position as a long-term catalyst play over the next 180 trading days.

Trade recap: Buy CABA at $3.00, stop $2.50, target $4.20, horizon long-term (180 trading days), risk level: high.